National Institute on Deafness and Other Communication Disorders; Notice of Closed Meetings, 12515 [2014-04767]
Download as PDF
<![CDATA[
Federal Register / Vol. 79, No. 43 / Wednesday, March 5, 2014 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
• HHS Reference No. E–055–2007/2—US
Provisional Patent Application No. 60/
957,140 filed 21 Aug 2007
• HHS Reference No. E–055–2007/3—PCT
Patent Application No. PCT/US2007/
086663 filed 06 Dec 2007, which published
as WO 2008/140602 on 20 Nov 2008, and
corresponding European Application No.
07874349.9; US Patent Application No. 12/
518,035 filed 05 Jun 2009
Licensing Contact: Cristina ThalhammerReyero, Ph.D., M.B.A.; 301–435–4507;
thalhamc@mail.nih.gov.
Collaborative Research Opportunity: The
National Institute of Allergy and Infectious
Diseases is seeking statements of capability
or interest from parties interested in
collaborative research to further develop,
evaluate or commercialize alpha-4 beta-7
integrin inhibitors. For collaboration
opportunities, please contact Bill
Ronnenberg, JD/MIP, MS at 301–451–3522 or
wr78k@nih.gov.
Beta-Amyloid and Tau Fibril Positron
Emissions Tomography (PET) Imaging
Agents
Description of Technology: The invention
relates to two novel classes of compounds
useful as radioligands for in vivo imaging of
beta-amyloid fibrils, peptides and plaques in
humans. Beta-amyloid peptide deposition in
the brain is a pathological feature of
Alzheimer’s disease (AD). Early detection of
beta-amyloid load in patients with suspected
AD is vital to initiating early treatment,
which can improve cognitive function and
quality of life for many patients. The
invention describes novel derivatives of
imidazopyridinylbenzeneamine (IMPY) and
benzothizolylbenzeneamine (BTA), which
demonstrate high in vitro binding affinity to
human beta-amyloid. The difference between
existing IMPY compounds and the novel
derivatives is the substitution of an aryl
halide with an aryl thioether group and
replacement of a sulfur group of the pyridine
ring with a nitrogen group. The new classes
of compounds have the potential of
providing improved amyloid imaging agents
for Positron Emission Tomography (PET)
with higher specificity for amyloid, low
background noise, better entry into the brain
and improved labeling efficiency.
Potential Commercial Applications:
• Alzheimer’s disease
• Alzheimer’s disease diagnostics
• Alzheimer’s disease early detection
Competitive Advantages: Specificity
Development Stage: In vitro data available
Inventors: Lisheng Cai, Victor W. Pike,
Robert B. Innis (all of NIMH)
Publications:
1. Nichols L, et al. Imaging and in vivo
quantitation of beta-amyloid: an exemplary
biomarker for Alzheimer’s disease? Biol
Psychiatry. 2006 May 15;59(10):940–7.
[PMID 16487944]
2. Toyama H, et al. PET imaging of brain with
the beta-amyloid probe, [11C]6–OH–BTA–
1, in a transgenic mouse model of
Alzheimer’s disease. Eur J Nucl Med Mol
Imaging. 2005 May;32(5):593–600. [PMID
15791432]
3. Cai L, et al. Synthesis and evaluation of
two 18F-labeled 6-iodo-2-(4’-N,N-
VerDate Mar<15>2010
17:13 Mar 04, 2014
Jkt 232001
dimethylamino)phenylimidazo[1,2a]pyridine derivatives as prospective
radioligands for beta-amyloid in
Alzheimer’s disease. J Med Chem. 2004
Apr 22;47(9):2208–18. [PMID 15084119]
Intellectual Property: HHS Reference No.
E–156–2006/0—
• US Patent Application 12/293,940 filed
September 17, 2008 (allowed)
• European Patent Application 07797254.5
filed April 19, 2007 (pending)
Related Technologies:
• HHS Reference No. E–136–2008/0—‘‘Beta
Amyloid PET Imaging Agents Based On 2(4-phenyl)benzo[d]thiazole Derivatives’’
• HHS Reference Nos. E–225–2011/0 and/
1—‘‘Beta-amyloid PET Imaging Agents
Based On Benzothiazoles (BTA)
Derivatives’’
Licensing Contact: Michael Shmilovich,
Esq., CLP; 301–435–5019; shmilovm@
mail.nih.gov.
Collaborative Research Opportunity: The
National Institute of Mental Health is seeking
statements of capability or interest from
parties interested in collaborative research to
further develop, evaluate or commercialize
Alzheimer’s disease diagnostics. For
collaboration opportunities, please contact
Suzanne Winfield, Ph.D. at 301–402–4324.
Dated: February 27, 2014.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2014–04771 Filed 3–4–14; 8:45 am]
BILLING CODE 4140–01–P
12515
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Kausik Ray, Ph.D.,
Scientific Review Officer, National Institute
on Deafness and Other Communication
Disorders, National Institutes of Health
Rockville, MD 20850, 301–402–3587, rayk@
nidcd.nih.gov.
Name of Committee: National Institute on
Deafness and Other Communication
Disorders Special Emphasis Panel; VSL
Translational Applications Review.
Date: March 27, 2014.
Time: 3:30 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
Neuroscience Center, 6001 Executive
Boulevard, Rockville, MD 20852 (Telephone
Conference Call).
Contact Person: Christine A. Livingston,
Ph.D., Scientific Review Officer, Division of
Extramural Activities, National Institutes of
Health/NIDCD, 6001 Executive Blvd.—Room
8343, Bethesda, MD 20892, (301) 496–8683,
livingsc@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.173, Biological Research
Related to Deafness and Communicative
Disorders, National Institutes of Health, HHS)
Dated: February 27, 2014.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2014–04767 Filed 3–4–14; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Deafness and
Other Communication Disorders;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Deafness and Other Communication
Disorders Special Emphasis Panel; Neural/
Vestibular Prosthesis Review.
Date: March 21, 2014.
Time: 2:00 p.m. to 3:30 p.m.
PO 00000
Frm 00054
Fmt 4703
Sfmt 4703
BILLING CODE 4140–01–P
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of K99 Grant Applications.
Date: March 25, 2014.
Time: 8:00 a.m. to 5:00 p.m.
E:\FR\FM\05MRN1.SGM
05MRN1
]]>Agencies
[Federal Register Volume 79, Number 43 (Wednesday, March 5, 2014)]
[Notices]
[Page 12515]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2014-04767]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Deafness and Other Communication Disorders;
Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Deafness and Other
Communication Disorders Special Emphasis Panel; Neural/Vestibular
Prosthesis Review.
Date: March 21, 2014.
Time: 2:00 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Kausik Ray, Ph.D., Scientific Review Officer,
National Institute on Deafness and Other Communication Disorders,
National Institutes of Health Rockville, MD 20850, 301-402-3587,
rayk@nidcd.nih.gov.
Name of Committee: National Institute on Deafness and Other
Communication Disorders Special Emphasis Panel; VSL Translational
Applications Review.
Date: March 27, 2014.
Time: 3:30 p.m. to 5:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, Neuroscience Center, 6001
Executive Boulevard, Rockville, MD 20852 (Telephone Conference
Call).
Contact Person: Christine A. Livingston, Ph.D., Scientific
Review Officer, Division of Extramural Activities, National
Institutes of Health/NIDCD, 6001 Executive Blvd.--Room 8343,
Bethesda, MD 20892, (301) 496-8683, livingsc@mail.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.173,
Biological Research Related to Deafness and Communicative Disorders,
National Institutes of Health, HHS)
Dated: February 27, 2014.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2014-04767 Filed 3-4-14; 8:45 am]
BILLING CODE 4140-01-P
